All News
Obinutuzumab drives histologic remission in lupus nephritis
At EULAR 2026, investigators are presenting perhaps the most biologically compelling data yet from the REGENCY trial, with evidence that obinutuzumab induces deep intrarenal B-cell depletion alongside markedly higher rates of histological remission.
Read Article
Do u screen your SLE pts for OP?
In this real-world multicenter study, SLE pts who were likely to be tested for BMD were older, had MSK s/sxs, sSJg & longer GC exposure.
RFs for OP: LN, higher dse. activity, longer GC use, high cumulative GC dose
POS1372 @RheumNow #EULAR2026 https://t.co/pAxhOPGGYs
sheila RHEUMarampa ( View Tweet)
#EULAR2026 POS1139 Pay attention in #SLE with anti-Sm+ RNP+. Data from 3 RCTs & a cohort:
-enriched in Black patients
-poor response to B-cell depletion inc. Obi
-non-response is assoc. with BAFF-dependent B-cell repopulation. So, use Belimumab
-High ferritin = flare @RheumNow https://t.co/3uDMigY8i2
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Abstr LB0003
Off-the-shelf allogeneic NK cell therapy + rituximab in refractory RA, Sjögren disease, and systemic sclerosis. 31 patients. Outpatient administered.
RA at 6 months: 71% ACR50, mean CDAI change −36.8. SSc: 100% rCRISS25 response. SjD: 86% ClinESSDAI responders. https://t.co/60046jgYia
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Interesting data on the effect of AB-101 + RTX on refractory RA, SSc and SjD.
Curious about long term results and potential position in tx strategies
LB0006 @RheumNow #EULAR2026 https://t.co/opbh8yGmwO
Links:
sheila RHEUMarampa ( View Tweet)
#SLE Rx options
Determining #MOA
#TYK2 #sig w #deucravacitinib
#IFN sig in active #SLE
⬇️ in
#anifrolumab
#upa
#deucra
#repeat renal #bx in #obinutuzimab ➡️
Clears B cells
#Dapriluzimab & other MOAs
⬇️AntiDNA
⬆️complements
#EULARbest @RheumNow #EULAR2026 #POS1364, OP0160,336
Janet Pope Janetbirdope ( View Tweet)
#EULAR2026 LB0003 CAR-T is not scalable. In a Phase 2a of off-the-shelf AB-101 allogenic NK + low dose conditioning (Cyclo & Flud) + Rituximab: preliminary efficacy & safety profile in severe-refractory RA (N=15), SjD (11), SSc (5). Longer FU & Comparator is needed @RheumNow https://t.co/gQniufREQC
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2026 LB0004 First BiTE, now TriTE! Tri-specific CC312 CD19/CD3/CD28 (i.e. CD28 co-stimulates Tcell activation) showed deep Bcell depletion, early efficacy & safety in 10 #SLE patients up to 52WKs. Promising but longer FU needed to see if repeat dosing needed @RheumNow https://t.co/6Lbm9LYJrY
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
JASMINE-SLE: Proof of concept study on
Nipocalimab for SLE
SRI-4 met at wk 24 for the 15 mg/kg q2w dose va. PBO
Improvement of SRI-4 composite & LLDAS at wk 52
LB0007 @RheumNow #EULAR2026 https://t.co/0wzHyid3dy
Links:
sheila RHEUMarampa ( View Tweet)
#EULAR2026 LB0006 Beyond conventional immunosuppressant, a multicentre RCT (N=145) in China showed mTOR-i Sirolimus + SOC met primary endpoint (SRI-4) vs PBO + SOC in #SLE. Favourable safety. Frequent AE: high cholesterol & low WCC. Unclear position in treatment pathway @RheumNow https://t.co/OiFp06467v
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
5 top abstracts in #Myositis @eular_org
1 #Nailfold #capillaries as an early marker of #IIM Rx
2 #brepocitinib +RCT #DM
3 & rapid skin improvement #CLASI
4 #Ab may help #IBM but neg primary endpoint
5 #criteria for #antisynthetase
#EULAR2026 @RheumNow
OP0168, 0166, 0164 POS264
Janet Pope Janetbirdope ( View Tweet)
Top 5 abst in #SjD
#anifrolumab +RCT
#ianalumab LTE Rx sustained
#telitatacept +LTE
#iana improves u/s parotids
#TYK2 sig in#SjD
OP0002, 0126, 127, 160 POS0284
#EULARbest #EULAR2026
@RheumNow @eular_org
Janet Pope Janetbirdope ( View Tweet)
#EULAR2026 LB0007 Phase 2 RCT of Nipocalimab, an FcRn-i in moderate-to-severe #SLE, with mandatory GC taper =<7.5mg/d by WK16: met primary endpoint at WK24 (SRI-4) vs PBO. Effect size better in Ab+, Ab-High & IFN-High. 23% had IgG<3 at WK58 but SIE. Phase 3 is underway @RheumNow https://t.co/EpgNOHcEqC
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Do you target #DORIS / remission in #SLE pts
#EULAR2026 @RheumNow @eular_org
Janet Pope Janetbirdope ( View Tweet)
Aiming for #DORIS #SLE #remission
Or #LLDAS in #SLE
Related to ⬆️survival
#deep outcome in RCTs
➡️archived in #deucravacitinib ph2 #LTE
&
ph3 #dapirolizumab & #obintuzimab
-achieved in #CAR-T trials in #lupus
POS0683, 1364, 0695, OP0338
& several 🚗 T abst
#EULAR2026 @RheumNow
Janet Pope Janetbirdope ( View Tweet)
Data of #Rituximab
In #SARD-ILD
Small N of #RA-#ILD pts
I think data are sufficient as #RWE of #RTX in RA-ILD
✅benefits in other #CTD ILD
✅benefits in #rheumatoid #arthritis
#EVER-ILD #RCT
HOT #RA-ILD topic June 5
#EULAR2026
@RheumNow https://t.co/61MbsnNsaf
Links:
Janet Pope Janetbirdope ( View Tweet)
Is there enough data to recommend
#rituximab
For #ILD in #rheumatoid #arthritis
@RheumNow #EULAR2026
Janet Pope Janetbirdope ( View Tweet)
TRM-SLE is a novel clinical outcome assessmentfor use in #SLE trials
8 domains: mucocutaneous, arthritis, hemolytic anemia, thrombocytopenia, nephropathy, serositis
Developed via multistage consensus process
Higher pt enrollment potential?
POS1068 @RheumNow #EULAR2026 https://t.co/W614xZV7TX
sheila RHEUMarampa ( View Tweet)
#EULAR2026 There are over 90 abstracts on CAR-T. Please read my article on a selection of abstracts pertaining to the progress of CAR-T in rheumatic and musculoskeletal diseases @RheumNow
https://t.co/2Uxy3uyF6H https://t.co/VulhEDJTEi
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
One of the highlights of #EULAR2026 for me:
♀️The "This Is a Woman's World" session
I recapped 8 must-know abstracts (including our work from ARCH_ArLAR) in a new @RheumNow video🎬
https://t.co/3jwJIegGg4 via @YouTube
@ArLARheumatolog https://t.co/Azvkl2sjdu
Links:
Nelly ZIADE 🍀 Nellziade ( View Tweet)
